Intestinal behavior of the ester prodrug tenofovir DF in humans

被引:28
作者
Geboers, Sophie [1 ]
Haenen, Steven [1 ]
Mols, Raf [1 ]
Brouwers, Joachim [1 ]
Tack, Jan [2 ]
Annaert, Pieter [1 ]
Augustijns, Patrick [1 ]
机构
[1] Katholieke Univ Leuven, Drug Delivery & Disposit, Dept Pharmaceut & Pharmacol Sci, B-3000 Leuven, Belgium
[2] Univ Hosp Leuven, Dept Gastroenterol, Louvain, Belgium
关键词
Tenofovir; Ester prodrug; Intestinal absorption behavior; Human intestinal fluids; Clinical trial; DISOPROXIL FUMARATE; INTRALUMINAL DRUG; FORMULATION BEHAVIOR; NUCLEOTIDE ANALOG; ABSORPTION; PLASMA; PHARMACOKINETICS; PHOSPHONATES; METABOLISM;
D O I
10.1016/j.ijpharm.2015.03.002
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Tenofovir-disoproxil-fumarate (TDF) is a double ester prodrug which enables intestinal uptake of tenofovir (TFV) after oral administration in humans. In this study, prodrug stability was monitored in situ in the human intestine and in vitro using biorelevant media. In fasted state human intestinal fluids, the prodrug was completely degraded within 90 min, resulting in the formation of the mono-ester intermediate and TFV; in fed state intestinal fluids, the degradation rate of TDF was slightly reduced and no TFV was formed. Intestinal fluid samples aspirated after administration of TDF confirmed extensive intraluminal degradation of TDF in fasted state conditions; a relatively fast absorption of TDF partly compensated for the degradation. Although food intake reduced intestinal degradation, the systemic exposure was not proportionally increased. The lower degradation in fed state conditions may be attributed to competing esterase substrates present in food, lower chemical degradation in the slightly more acidic environment and micellar entrapment, delaying exposure to the "degrading" intestinal environment. The results of this study demonstrate premature intestinal degradation of TDF and suggest that TFV may benefit from a more stable prodrug approach; however, fast absorption may compensate for fast degradation, indicating that prodrug selection should not be limited to stability assays. (C) 2015 Elsevier B.V. All rights reserved.
引用
收藏
页码:131 / 137
页数:7
相关论文
共 24 条
[1]  
Augustijns P., 2013, EUR J PHARM SCI
[2]   Phase I/II trial of the pharmacokinetics, safety, and antiretroviral activity of tenofovir disoproxil fumarate in human immunodeficiency virus-infected adults [J].
Barditch-Crovo, P ;
Deeks, SG ;
Collier, A ;
Safrin, S ;
Coakley, DF ;
Miller, M ;
Kearney, BP ;
Coleman, RL ;
Lamy, PD ;
Kahn, JO ;
McGowan, I ;
Lietman, PS .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2001, 45 (10) :2733-2739
[3]   Assessment of enzymatic prodrug stability in human, dog and simulated intestinal fluids [J].
Borde, A. S. ;
Karlsson, E. M. ;
Andersson, K. ;
Bjorhall, K. ;
Lennernas, H. ;
Abrahamsson, B. .
EUROPEAN JOURNAL OF PHARMACEUTICS AND BIOPHARMACEUTICS, 2012, 80 (03) :630-637
[4]   Intraluminal drug and formulation behavior and integration in in vitro permeability estimation:: A case study with amprenavir [J].
Brouwers, J ;
Tack, J ;
Lammert, F ;
Augustijns, P .
JOURNAL OF PHARMACEUTICAL SCIENCES, 2006, 95 (02) :372-383
[5]   Parallel monitoring of plasma and intraluminal drug concentrations in man after oral administration of fosamprenavir in the fasted and fed state [J].
Brouwers, Joachim ;
Tack, Jan ;
Augustijns, Patrick .
PHARMACEUTICAL RESEARCH, 2007, 24 (10) :1862-1869
[6]   Resolving intraluminal drug and formulation behavior: Gastrointestinal concentration profiling in humans [J].
Brouwers, Joachim ;
Augustijns, Patrick .
EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES, 2014, 61 :2-10
[7]   Intestinal drug solubility estimation based on simulated intestinal fluids: Comparison with solubility in human intestinal fluids [J].
Clarysse, Sarah ;
Brouwers, Joachim ;
Tack, Jan ;
Annaert, Pieter ;
Augustijns, Patrick .
EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES, 2011, 43 (04) :260-269
[8]   Pharmacokinetics and bioavailability of the anti-human immunodeficiency virus nucleotide analog 9-[(R)-2-(phosphonomethoxy)propyl]adenine (PMPA) in dogs [J].
Cundy, KC ;
Sueoka, C ;
Lynch, GR ;
Griffin, L ;
Lee, WA ;
Shaw, JP .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1998, 42 (03) :687-690
[9]  
Fardis M., 2007, CASE STUDY TENOFOVIR
[10]   Absorption rate limit considerations for oral phosphate prodrugs [J].
Heimbach, T ;
Oh, DM ;
Li, LY ;
Forsberg, M ;
Savolainen, J ;
Leppänen, J ;
Matsunaga, Y ;
Flynn, G ;
Fleisher, D .
PHARMACEUTICAL RESEARCH, 2003, 20 (06) :848-856